ICT
MCID: CRC014
MIFTS: 51

Carcinoid Tumors, Intestinal (ICT)

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Carcinoid Tumors, Intestinal

MalaCards integrated aliases for Carcinoid Tumors, Intestinal:

Name: Carcinoid Tumors, Intestinal 58 13
Gastrointestinal Carcinoid Tumor 76 56 74
Carcinoid 76 38 56
Malignant Carcinoid Syndrome 60 74
Carcinoid Tumor 45 74
Argentaffinoma 76 74
Carcinoid Tumor No Icd-O Subtype 74
Tumor, Carcinoid, Intestinal 41
Carcinoid Tumor of Intestine 74
Intestinal Carcinoid Tumor 76
Carcinoid Syndrome 60
Ict 76

Characteristics:

OMIM:

58
Inheritance:
autosomal dominant


HPO:

33
carcinoid tumors, intestinal:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 60  
Rare endocrine diseases


External Ids:

OMIM 58 114900
KEGG 38 H00034
MeSH 45 D002276
ICD10 via Orphanet 35 E34.0
Orphanet 60 ORPHA100093
MedGen 43 C0349535
SNOMED-CT via HPO 70 263681008

Summaries for Carcinoid Tumors, Intestinal

UniProtKB/Swiss-Prot : 76 Intestinal carcinoid tumor: A yellow, well-differentiated, circumscribed tumor that arises from enterochromaffin cells in the small intestine or, less frequently, in other parts of the gastrointestinal tract.

MalaCards based summary : Carcinoid Tumors, Intestinal, also known as gastrointestinal carcinoid tumor, is related to pulmonary blastoma and serotonin syndrome. An important gene associated with Carcinoid Tumors, Intestinal is SDHD (Succinate Dehydrogenase Complex Subunit D), and among its related pathways/superpathways are Transcriptional misregulation in cancer and Neuroscience. The drugs Oxaliplatin and Cola have been mentioned in the context of this disorder. Affiliated tissues include lung, small intestine and bone, and related phenotypes are intestinal carcinoid and nausea and vomiting

Description from OMIM: 114900

Related Diseases for Carcinoid Tumors, Intestinal

Diseases related to Carcinoid Tumors, Intestinal via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 624)
# Related Disease Score Top Affiliating Genes
1 pulmonary blastoma 31.8 CHGA NKX2-1 SYP
2 serotonin syndrome 31.8 CHGA MEN1 NOTCH1 SST
3 goblet cell carcinoid 30.9 CHGA ENO2
4 cystic teratoma 30.5 ENO2 NKX2-1 SYP
5 cystadenoma 30.4 CHGA SYP
6 lung oat cell carcinoma 30.4 CHGA ENO2
7 spinal meningioma 30.3 CHGA ENO2
8 horseshoe kidney 30.1 CHGA ENO2 NKX2-1 SYP
9 small cell carcinoma 30.0 CHGA ENO2 NKX2-1 SYP
10 tubular adenocarcinoma 30.0 CHGA SYP
11 gastric tubular adenocarcinoma 30.0 CHGA SYP
12 ganglioneuroblastoma 30.0 ENO2 SYP
13 sclerosing hemangioma 29.9 CHGA NKX2-1 SYP
14 benign ependymoma 29.8 ENO2 SYP
15 paragangliomas 1 29.8 CHGA SDHD
16 large cell neuroendocrine carcinoma 29.8 CHGA ENO2 NKX2-1 SYP
17 multiple endocrine neoplasia, type iia 29.7 MEN1 SDHD
18 gastric neuroendocrine neoplasm 29.7 CHGA SST
19 glomus tumor 29.7 ENO2 SDHD SYP
20 zollinger-ellison syndrome 29.7 CHGA MEN1 SST
21 vipoma 29.7 CHGA SST
22 middle ear adenoma 29.7 ENO2 SYP
23 pulmonary sclerosing hemangioma 29.7 CHGA NKX2-1 SYP
24 somatostatinoma 29.6 CHGA ENO2 SST
25 hemangioma 29.6 CHGA ENO2 NKX2-1 SYP
26 pituitary tumors 29.6 MEN1 SST
27 teratoma 29.6 ENO2 NKX2-1 SYP
28 paraganglioma 29.5 CHGA ENO2 SDHD SST SYP
29 pituitary adenoma, prolactin-secreting 29.5 MEN1 SST SSTR2
30 collagenous colitis 29.5 CHGA CHGB
31 gastrinoma 29.5 CHGA MEN1 SST
32 islet cell tumor 29.4 CHGA MEN1 SST
33 ependymoma 29.4 ENO2 MEN1 SYP
34 insulinoma 29.4 CHGA MEN1 SST
35 acromegaly 29.4 MEN1 SST SSTR2
36 ectopic cushing syndrome 29.3 MEN1 SST SYP
37 von hippel-lindau syndrome 29.2 CHGA CHGB MEN1 SDHD
38 malignant pheochromocytoma 29.0 CHGA ENO2 SST SYP
39 endocrine gland cancer 29.0 CHGA MEN1 SST SYP
40 carcinoid syndrome 29.0 CHGA ENO2 MEN1 SST SYP
41 duodenal gastrinoma 28.9 CHGA ENO2 MEN1 SST
42 medulloblastoma 28.9 ENO2 NOTCH1 SSTR2 SYP
43 gastrointestinal stromal tumor 28.8 CHGA ENO2 MEN1 SDHD SYP
44 meningioma, familial 28.8 ENO2 MEN1 SST SSTR2 SYP
45 multiple endocrine neoplasia, type i 28.6 CHGA MEN1 SDHD SST SYP
46 small cell cancer of the lung 28.5 CHGA ENO2 NKX2-1 SST SSTR2 SYP
47 thyroid carcinoma, familial medullary 28.1 CHGA CHGB ENO2 MEN1 NKX2-1 SST
48 pheochromocytoma 27.9 CHGA CHGB ENO2 MEN1 SDHD SST
49 neuroendocrine tumor 27.8 CHGA CHGB ENO2 MEN1 NKX2-1 SST
50 appendix carcinoid tumor 12.4

Graphical network of the top 20 diseases related to Carcinoid Tumors, Intestinal:



Diseases related to Carcinoid Tumors, Intestinal

Symptoms & Phenotypes for Carcinoid Tumors, Intestinal

Human phenotypes related to Carcinoid Tumors, Intestinal:

60 33 (show all 27)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 intestinal carcinoid 60 33 Frequent (79-30%) HP:0006723
2 nausea and vomiting 60 Occasional (29-5%)
3 myopathy 60 Very rare (<4-1%)
4 elevated hepatic transaminase 60 Occasional (29-5%)
5 asthma 60 Occasional (29-5%)
6 carcinoid tumor 60 Obligate (100%)
7 episodic abdominal pain 60 Frequent (79-30%)
8 tricuspid regurgitation 60 Occasional (29-5%)
9 night sweats 60 Frequent (79-30%)
10 palpitations 60 Occasional (29-5%)
11 paraganglioma 60 Very rare (<4-1%)
12 increased lacrimation 60 Occasional (29-5%)
13 heart murmur 60 Occasional (29-5%)
14 rhinorrhea 60 Occasional (29-5%)
15 pulmonary carcinoid tumor 60 Occasional (29-5%)
16 increased serum serotonin 60 Occasional (29-5%)
17 protracted diarrhea 60 Frequent (79-30%)
18 chronic noninfectious lymphadenopathy 60 Occasional (29-5%)
19 right ventricular failure 60 Occasional (29-5%)
20 hepatic necrosis 60 Very rare (<4-1%)
21 erythematous plaque 60 Frequent (79-30%)
22 facial telangiectasia 60 Occasional (29-5%)
23 small intestine carcinoid 60 Frequent (79-30%)
24 lack of bowel sounds 60 Very rare (<4-1%)
25 bronchospasm 60 Occasional (29-5%)
26 abnormal b-type natriuretic peptide level 60 Occasional (29-5%)
27 atypical pulmonary carcinoid tumor 60 Very rare (<4-1%)

Symptoms via clinical synopsis from OMIM:

58
Oncology:
intestinal carcinoid
appendiceal carcinoid
malignant carcinoid of ileum

Clinical features from OMIM:

114900

MGI Mouse Phenotypes related to Carcinoid Tumors, Intestinal:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.65 MEN1 NKX2-1 NOTCH1 SST SSTR2
2 endocrine/exocrine gland MP:0005379 9.63 CHGA CHGB MEN1 NKX2-1 NOTCH1 SDHD
3 homeostasis/metabolism MP:0005376 9.56 CHGA CHGB MEN1 NKX2-1 NOTCH1 SDHD
4 nervous system MP:0003631 9.32 CHGA CHGB ENO2 MEN1 NKX2-1 NOTCH1

Drugs & Therapeutics for Carcinoid Tumors, Intestinal

Drugs for Carcinoid Tumors, Intestinal (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 155)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 61825-94-3 43805 6857599 5310940 9887054
2 Cola Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
3 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 1 68538-85-2
5
leucovorin Approved Phase 2, Phase 3,Phase 3,Phase 1 58-05-9 143 6006
6
Fluorouracil Approved Phase 2, Phase 3,Phase 1 51-21-8 3385
7
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
8
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
9
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
10
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
11
Ondansetron Approved Phase 3 99614-02-5 4595
12
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 46835353 5284616 6436030
13
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 70789204 6442177
14
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
15 Pancreatic Polypeptide Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 59763-91-6
16 Folate Phase 2, Phase 3
17 Vitamin B9 Phase 2, Phase 3
18 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
19 Immunologic Factors Phase 2, Phase 3,Phase 3,Phase 1
20 Immunosuppressive Agents Phase 2, Phase 3,Phase 3,Phase 1
21 Antimetabolites Phase 2, Phase 3,Phase 1
22 Antineoplastic Agents, Immunological Phase 2, Phase 3,Phase 1
23 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
24 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
25
protease inhibitors Phase 3,Phase 2
26 HIV Protease Inhibitors Phase 3,Phase 2
27 Central Nervous System Depressants Phase 3
28 Peripheral Nervous System Agents Phase 3,Phase 2
29 Analgesics, Opioid Phase 3
30 Anesthetics Phase 3
31 Anesthetics, Intravenous Phase 3
32 Narcotics Phase 3
33 Anesthetics, General Phase 3
34 Adjuvants, Anesthesia Phase 3
35 Analgesics Phase 3
36 Antiemetics Phase 3,Phase 2
37 Antipsychotic Agents Phase 3
38 Hormone Antagonists Phase 3,Phase 2,Phase 1
39 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1
40 Anti-Anxiety Agents Phase 3
41 Dermatologic Agents Phase 3,Not Applicable
42 Antipruritics Phase 3
43 glucocorticoids Phase 3
44 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
45 Tranquilizing Agents Phase 3
46 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
47 Serotonin Agents Phase 3,Phase 2
48 Serotonin Antagonists Phase 3,Phase 2
49 Neurotransmitter Agents Phase 3,Phase 2
50 Hormones Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 61)
# Name Status NCT ID Phase Drugs
1 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
2 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
3 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
4 Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen Completed NCT00016380 Phase 3 dexamethasone;ondansetron
5 Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery Recruiting NCT03375320 Phase 3 Cabozantinib S-malate
6 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
7 A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers Recruiting NCT02923934 Phase 2 Ipilimumab;Nivolumab
8 Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors Completed NCT00002470 Phase 2 fluorouracil
9 PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2 bortezomib
10 Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2 octreotide acetate;vatalanib
11 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
12 Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors Completed NCT00055809 Phase 2
13 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
14 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
15 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2 thalidomide
16 Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma Completed NCT00093782 Phase 2 temsirolimus
17 Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer Completed NCT00019474 Phase 2 fluorouracil;hydroxyurea
18 Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction Completed NCT00004911 Phase 1, Phase 2
19 Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction Completed NCT00004910 Phase 1, Phase 2
20 Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs Recruiting NCT03722511 Phase 2
21 Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer Terminated NCT00903396 Phase 2 palonosetron hydrochloride
22 Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer Completed NCT00005049 Phase 2 carboplatin;cisplatin;floxuridine
23 Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Terminated NCT00084461 Phase 2 romidepsin
24 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors Active, not recruiting NCT02259725 Phase 2 regorafenib
25 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
26 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
27 Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors Active, not recruiting NCT01841736 Phase 2 Pazopanib;Pazopanib Hydrochloride
28 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
29 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
30 Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2 octreotide acetate
31 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2 isolated perfusion;melphalan
32 Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions Unknown status NCT00066404 Phase 1
33 Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors Completed NCT00049023 Phase 1
34 Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer Completed NCT00654160 Phase 1 fluorouracil;irinotecan hydrochloride;leucovorin calcium
35 Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features Completed NCT01048892 Phase 1 cyclophosphamide
36 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
37 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
38 Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer Completed NCT00003427 Phase 1 irinotecan hydrochloride;oxaliplatin
39 Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors Completed NCT01155258 Phase 1 temsirolimus;vinorelbine ditartrate
40 Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Completed NCT00655655 Phase 1 everolimus;vatalanib
41 Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Completed NCT00397384 Phase 1 cetuximab;erlotinib hydrochloride
42 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
43 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
44 Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1 Everolimus;Octreotide Acetate
45 Interleukin-12 in Treating Patients With Cancer in the Abdomen Completed NCT00003046 Phase 1
46 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
47 Irinotecan and Capecitabine in Treating Patients With Solid Tumors Completed NCT00003867 Phase 1 capecitabine;irinotecan hydrochloride
48 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1 entinostat
49 Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer Completed NCT00003439 Phase 1
50 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib

Search NIH Clinical Center for Carcinoid Tumors, Intestinal

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: carcinoid tumor

Genetic Tests for Carcinoid Tumors, Intestinal

Anatomical Context for Carcinoid Tumors, Intestinal

MalaCards organs/tissues related to Carcinoid Tumors, Intestinal:

42
Lung, Small Intestine, Bone, Pituitary, Liver, Heart, Thyroid

Publications for Carcinoid Tumors, Intestinal

Articles related to Carcinoid Tumors, Intestinal:

(show all 23)
# Title Authors Year
1
Synchronous Gastrointestinal Carcinoid Tumor and Colon Adenocarcinoma: Case Reports and Literature Review. ( 28584225 )
2017
2
Bilateral Extraocular Muscle Metastases From a Gastrointestinal Carcinoid Tumor. ( 26767734 )
2016
3
Cardiac manifestations of gastrointestinal carcinoid tumor. ( 23834689 )
2013
4
Costal metastasis: A singular localization of gastrointestinal carcinoid tumor. ( 22558016 )
2012
5
Succinate dehydrogenase gene variants and their role in Cowden syndrome. ( 21565294 )
2011
6
Gastrointestinal carcinoid tumor and chylous ascites, a rare association with a poor prognosis. A case report. ( 18705413 )
2008
7
Germline mutations and variants in the succinate dehydrogenase genes in Cowden and Cowden-like syndromes. ( 18678321 )
2008
8
Metastatic Gastrointestinal Carcinoid Tumor with Unknown Primary Site. ( 27303478 )
2007
9
Nuclear translocation of beta-catenin protein but absence of beta-catenin and APC mutation in gastrointestinal carcinoid tumor. ( 17009161 )
2006
10
Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by notch signaling. ( 15870121 )
2005
11
Insulin-like growth factor 1 signaling in human gastrointestinal carcinoid tumor cells. ( 15657590 )
2004
12
Identification of novel SDHD mutations in patients with phaeochromocytoma and/or paraganglioma. ( 12111639 )
2002
13
Alterations of the SDHD gene locus in midgut carcinoids, Merkel cell carcinomas, pheochromocytomas, and abdominal paragangliomas. ( 12007193 )
2002
14
Gastrointestinal carcinoid tumor in a patient with chronic diarrhea. ( 11784227 )
2002
15
Absence of somatic SDHD mutations in sporadic neuroendocrine tumors and detection of two germline variants in paraganglioma patients. ( 12386824 )
2002
16
Carcinoid syndrome from gastrointestinal carcinoid tumor without distant metastases. ( 12080244 )
2002
17
Accumulation of beta-catenin protein and mutations in exon 3 of beta-catenin gene in gastrointestinal carcinoid tumor. ( 11559529 )
2001
18
Strip biopsy for gastrointestinal carcinoid tumor. ( 9610665 )
1998
19
[Gastrointestinal carcinoid tumor--an immunohistochemical and histochemical study]. ( 1723678 )
1991
20
Gastrointestinal carcinoid tumor metastatic to the orbit. ( 2688132 )
1989
21
Ampullary somatostatinoma: psammomatous variant of gastrointestinal carcinoid tumor--an immunohistochemical and ultrastructural study. Report of a case and review of the literature. ( 6314801 )
1983
22
Whole abdominal radiation in the management of metastatic gastrointestinal carcinoid tumor. ( 6174487 )
1981
23
Association of gastrointestinal carcinoid tumor with cardiovascular abnormalities. ( 13248872 )
1955

Variations for Carcinoid Tumors, Intestinal

ClinVar genetic disease variations for Carcinoid Tumors, Intestinal:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 SDHD NM_003002.3(SDHD): c.149A> G (p.His50Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs11214077 GRCh37 Chromosome 11, 111958677: 111958677
2 SDHD NM_003002.3(SDHD): c.149A> G (p.His50Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs11214077 GRCh38 Chromosome 11, 112087953: 112087953

Expression for Carcinoid Tumors, Intestinal

Search GEO for disease gene expression data for Carcinoid Tumors, Intestinal.

Pathways for Carcinoid Tumors, Intestinal

Pathways related to Carcinoid Tumors, Intestinal according to KEGG:

38
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202

Pathways related to Carcinoid Tumors, Intestinal according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.46 ENO2 NKX2-1 NOTCH1 SYP

GO Terms for Carcinoid Tumors, Intestinal

Biological processes related to Carcinoid Tumors, Intestinal according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 brain development GO:0007420 9.58 MEN1 NKX2-1 NOTCH1
2 oligodendrocyte differentiation GO:0048709 9.37 NKX2-1 NOTCH1
3 endoderm development GO:0007492 9.32 NKX2-1 NOTCH1
4 neuron fate commitment GO:0048663 9.26 NKX2-1 NOTCH1
5 negative regulation of cell proliferation GO:0008285 9.26 MEN1 NOTCH1 SST SSTR2
6 negative regulation of cell-substrate adhesion GO:0010812 9.16 MEN1 NOTCH1
7 forebrain development GO:0030900 8.8 NKX2-1 NOTCH1 SSTR2

Sources for Carcinoid Tumors, Intestinal

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....